These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 26219417)

  • 1. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies.
    Saad F; Yassin A; Doros G; Haider A
    Int J Obes (Lond); 2016 Jan; 40(1):162-70. PubMed ID: 26219417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
    Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
    Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy.
    Salman M; Yassin DJ; Shoukfeh H; Nettleship JE; Yassin A
    Aging Male; 2017 Mar; 20(1):45-48. PubMed ID: 28084147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss.
    Saad F; Haider A; Doros G; Traish A
    Obesity (Silver Spring); 2013 Oct; 21(10):1975-81. PubMed ID: 23512691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study.
    Yassin AA; Nettleship J; Almehmadi Y; Salman M; Saad F
    Andrologia; 2016 Sep; 48(7):793-9. PubMed ID: 26762680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study.
    Saad F; Doros G; Haider KS; Haider A
    Int J Obes (Lond); 2020 Jun; 44(6):1264-1278. PubMed ID: 32060355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study.
    Haider A; Saad F; Doros G; Gooren L
    Obes Res Clin Pract; 2014; 8(4):e339-49. PubMed ID: 25091355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
    Yassin AA; Nettleship JE; Salman M; Almehmadi Y
    Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
    Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
    Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss.
    Yassin A; Doros G
    Clin Obes; 2013 Jun; 3(3-4):73-83. PubMed ID: 24163704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
    Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study).
    Shigehara K; Konaka H; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Iwamoto T; Koh E; Mizokami A; Namiki M
    Andrologia; 2018 Feb; 50(1):. PubMed ID: 28497534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
    J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
    Yassin DJ; Doros G; Hammerer PG; Yassin AA
    J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports.
    Saad F; Yassin A; Almehmadi Y; Doros G; Gooren L
    Aging Male; 2015; 18(3):164-8. PubMed ID: 26075537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
    Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
    Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study.
    Haider KS; Haider A; Doros G; Traish A
    J Urol; 2018 Jan; 199(1):257-265. PubMed ID: 28728990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.